What care plan do you recommend for a patient with acute non‑productive cough, clear chest X‑ray, negative respiratory panel, who is currently on Trelegy (fluticasone furoate/umeclidinium/vilanterol) 100 mcg/62.5 mcg/25 mcg inhalation?

Discontinue Trelegy Immediately – It Is Not Indicated for Acute Cough

Trelegy (fluticasone furoate/umeclidinium/vilanterol) is contraindicated for acute symptoms and should be stopped immediately in this patient with acute non-productive cough. 1 The FDA label explicitly states Trelegy is "not indicated for relief of acute bronchospasm" and is only approved for maintenance treatment of COPD and asthma in patients 18 years and older—not for acute cough management. 1

Why Trelegy Is Inappropriate Here

This patient presents with:

• Acute cough (duration not specified as chronic)
• Clear chest X-ray
• Negative respiratory panel
• Non-productive cough that clears periodically

None of these findings support initiating triple therapy with an ICS/LAMA/LABA combination. The patient has no documented diagnosis of COPD or asthma requiring maintenance therapy. Starting Trelegy for an acute cough represents a fundamental misapplication of this medication and exposes the patient to unnecessary risks including pneumonia, oral candidiasis, cardiovascular effects, and adrenal suppression. 1

Recommended Care Plan

Step 1: Immediate Actions

• Discontinue Trelegy – Document that this was started inappropriately for acute cough
• Reassess the clinical picture – Determine cough duration precisely (acute <3 weeks, subacute 3-8 weeks, chronic >8 weeks) 2, 3

Step 2: Rule Out Red Flags

Screen for concerning features that would require urgent evaluation: 2

• Hemoptysis
• Smoker >45 years with new/changed cough
• Prominent dyspnea at rest or night
• Systemic symptoms (fever, weight loss)
• Hoarseness
• Recurrent pneumonia
• Abnormal respiratory exam

If any red flags present: Proceed with targeted workup (CT chest, bronchoscopy, specialist referral as indicated)

Step 3: Classify and Treat Based on Duration

If Acute Cough (<3 weeks):

Most likely viral upper respiratory infection (common cold) or acute bronchitis. 3, 4

Treatment:

• First-generation antihistamine/decongestant (e.g., chlorpheniramine/pseudoephedrine) unless contraindicated by glaucoma, BPH, hypertension, or renal failure 4
• Alternative: Naproxen 220-440 mg twice daily if NSAIDs not contraindicated 4
• Avoid: Antibiotics (not effective for viral acute cough), newer non-sedating antihistamines (ineffective), codeine-based cough suppressants 4
• Do NOT use: Over-the-counter combination products unless they contain first-generation antihistamine/decongestant 4

If Subacute Cough (3-8 weeks):

Determine if post-infectious versus other cause. 3

If post-infectious:

• Consider post-viral bronchial hyperresponsiveness
• Trial of inhaled corticosteroid (e.g., fluticasone 250 mcg twice daily) for 2-4 weeks 5
• If no response, proceed to chronic cough algorithm

If Chronic Cough (>8 weeks):

Systematic empiric treatment targeting most common causes: 3

Sequential approach:

1. Upper Airway Cough Syndrome (UACS) – First-line

   • Oral first-generation antihistamine/decongestant for 2-4 weeks 3
   • If prominent nasal symptoms: Add intranasal corticosteroid 5

2. Asthma/Cough-Variant Asthma – Second-line

   • Perform spirometry with bronchodilator response 5
   • If normal spirometry: Consider bronchoprovocation testing (methacholine challenge) 5
   • Trial: Inhaled corticosteroid + LABA for 4-8 weeks 3
   • If inadequate response: Add 2-week oral prednisone 40 mg daily trial 3, 5
   • Cough unlikely due to eosinophilic inflammation if no response to 2-week oral steroid trial 5

3. Gastroesophageal Reflux Disease (GERD) – Third-line

   • Intensive acid suppression: High-dose PPI (e.g., omeprazole 40 mg twice daily) + alginate for minimum 3 months 3, 5
   • Add lifestyle modifications (elevate head of bed, avoid late meals, weight loss)
   • Consider adding prokinetic (metoclopramide) if partial response 3
   • GERD-related cough often occurs without GI symptoms 5

4. Non-Asthmatic Eosinophilic Bronchitis (NAEB)

   • Requires induced sputum for eosinophil count if available 3
   • Treat with inhaled corticosteroids if confirmed

Step 4: Medication Review

• Check if patient takes ACE inhibitor – If yes, discontinue for at least 4 weeks and substitute with ARB 2, 5
• Assess smoking status – If smoker, counsel on cessation as smoking is dose-related cause of chronic cough 5

Step 5: Follow-Up Protocol

• Schedule follow-up in 4-6 weeks after each therapeutic trial 2, 3
• Assess compliance at each visit – verify patient understands and can perform treatments 2
• Maintain partially effective treatments when adding next therapy (multiple causes often coexist) 3
• Use validated tools: Cough visual analog scale or cough-specific quality of life questionnaire to track response 5

Step 6: Refractory Cough

If systematic trials of UACS, asthma, and GERD treatments fail after 3+ months: 2, 3

• Consider HRCT chest to evaluate for bronchiectasis, interstitial lung disease
• Consider bronchoscopy for occult airway disease
• Refer to specialized cough clinic 2, 5
• Consider off-label gabapentin or low-dose morphine for refractory unexplained chronic cough 6

Critical Pitfalls to Avoid

1. Do not continue Trelegy – This represents inappropriate polypharmacy and medication misuse
2. Do not prescribe antibiotics for acute non-productive cough with clear CXR and negative respiratory panel 4
3. Do not use newer non-sedating antihistamines (cetirizine, loratadine) for acute cough—they are ineffective 4
4. Do not diagnose "acute bronchitis" without ruling out common cold first—this leads to inappropriate antibiotic prescribing 4
5. Do not give up after single treatment failure – Chronic cough often has multiple simultaneous causes requiring additive sequential therapy 3, 5
6. Do not skip GERD trial even without GI symptoms – reflux-associated cough frequently presents without heartburn 5
7. Do not undertrial GERD therapy – Requires high-dose PPI for minimum 3 months, not 2-4 weeks 3, 5

Summary Algorithm

Acute cough + clear CXR + negative panel = First-generation antihistamine/decongestant OR naproxen for 1-2 weeks

If persists >3 weeks = Post-infectious cough trial: ICS for 2-4 weeks

If persists >8 weeks = Chronic cough protocol:

1. UACS treatment (2-4 weeks)
2. Add asthma treatment if inadequate response (4-8 weeks)
3. Add GERD treatment if still inadequate (3 months minimum)
4. Maintain all partially effective treatments
5. Refer to cough specialist if refractory

Throughout: Stop Trelegy, check for ACE inhibitor use, assess smoking, follow up every 4-6 weeks, verify compliance